IRIDEX (NASDAQ:IRIX) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

IRIDEX (NASDAQ:IRIX) released its quarterly earnings results on Tuesday. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06), Zacks reports. The company had revenue of $12.57 million during the quarter, compared to analyst estimates of $13.59 million.

Here are the key takeaways from IRIDEX’s conference call:

• Glaucoma remained a growth engine, with Cyclo G6 probe volume up 35% year over year to 17,700 units and G6 product-family revenue up 19% to $3.9 million, supported by higher utilization, reimbursement tailwinds, targeted physician outreach, and higher U.S. pricing.
• IRIDEX generated positive cash flow in the quarter while reducing operating expenses 5% year over year to $5.3 million. Management expects the headquarters relocation and shift to lower-cost contract manufacturing to improve margins and cash generation, particularly in 2027.
• Second-quarter revenue fell 7% to $12.6 million, primarily because retina revenue declined to $6.5 million from $8.0 million. Retina performance was affected by international commercial transitions, regulatory constraints, distributor inventory issues, and operational execution challenges.
• Management reaffirmed 2026 revenue guidance of $51 million to $53 million, excluding the Middle East, implying 1% to 5% pro forma growth. The company expects low-single-digit retina growth and low-double-digit glaucoma probe growth in the second half, but warned that international ordering may remain uneven and that safety-stock investments will reduce cash on hand through 2026.

IRIDEX Trading Up 5.7%

Shares of IRIX opened at $0.93 on Wednesday. The stock has a market cap of $16.19 million, a P/E ratio of -4.90 and a beta of 0.66. The company has a 50-day moving average of $1.01 and a two-hundred day moving average of $1.13. IRIDEX has a 12-month low of $0.80 and a 12-month high of $1.65.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $3.00.

Institutional Trading of IRIDEX

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC increased its position in IRIDEX by 93.9% during the 4th quarter. Jane Street Group LLC now owns 31,758 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 15,377 shares in the last quarter. Apexium Financial LP raised its stake in IRIDEX by 53.0% in the 3rd quarter. Apexium Financial LP now owns 100,529 shares of the medical equipment provider’s stock valued at $116,000 after purchasing an additional 34,834 shares during the last quarter. Susquehanna International Group LLP lifted its holdings in IRIDEX by 46.2% in the 3rd quarter. Susquehanna International Group LLP now owns 56,470 shares of the medical equipment provider’s stock valued at $65,000 after purchasing an additional 17,834 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in shares of IRIDEX by 62.7% during the 3rd quarter. Citadel Advisors LLC now owns 109,473 shares of the medical equipment provider’s stock worth $126,000 after purchasing an additional 42,202 shares during the last quarter. 20.10% of the stock is currently owned by hedge funds and other institutional investors.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration.